HPS antioxidant trial

HPS antioxidant study, 2002	TRC3698
	download pdf: combination \| antioxydants for cardiovascular prevention

Treatments

Studied treatment	antioxidant vitamin supplementation (600 mg vitamin E, 250 mg vitamin C, and 20 mg -carotene daily)
Control treatment	matching placebo
Remarks	factorial design with cholesterol lowering therapy

Patients	UK adults (aged 40–80) with coronary disease, other occlusive arterial disease, or diabetes
Inclusion criteria	Men and women; aged about 40 years to 80 years; non-fasting blood total cholesterol concentrations of at least 3·5 mmol/L; substantial 5-year risk of death from coronary heart disease because of a past medical history of coronary heart disease, of other occlusive arterial disease, of diabetes mellitus, or of treated hypertension alone
Exclusion criteria	life-threatening conditions, such as chronic liver disease, severe renal disease, severe heart failure, severe chronic airways disease, or diagnosed cancer (other than non-melanoma skin cancer); high-dose vitamin E supplements

Endpoint Studied treat.
n/N Control treat.
n/N Graph RR [95% CI]

Coronary event

1063 / 10269
1047 / 10267
1,02 [0,94;1,10]

stroke (fatal and non fatal)

511 / 10269
518 / 10267
0,99 [0,88;1,11]

Cardiovascular death

878 / 10269
840 / 10267
1,05 [0,95;1,14]

cardiovascular events

2306 / 10269
2312 / 10267
1,00 [0,95;1,05]

All cause death

1446 / 10269
1389 / 10267
1,04 [0,97;1,11]

Non fatal stroke

430 / 10269
435 / 10267
0,99 [0,87;1,13]

Non fatal MI

464 / 10269
467 / 10267
0,99 [0,88;1,13] 0 2 1.0

Endpoint	Events (%)		Relative Risk	95% CI	Endpoint definition in the trial	Ref
Relative risks
Endpoint	Studied treat.	Control treat.	Relative Risk	95% CI	Endpoint definition in the trial	Ref
Coronary event	1063 / 10269 (10,4%)	1047 / 10267 (10,2%)	1,02	[0,94;1,10]		2942
stroke (fatal and non fatal)	511 / 10269 (5,0%)	518 / 10267 (5,0%)	0,99	[0,88;1,11]		2942
Cardiovascular death	878 / 10269 (8,6%)	840 / 10267 (8,2%)	1,05	[0,95;1,14]		2942
cardiovascular events	2306 / 10269 (22,5%)	2312 / 10267 (22,5%)	1,00	[0,95;1,05]	fig 3	2942
All cause death	1446 / 10269 (14,1%)	1389 / 10267 (13,5%)	1,04	[0,97;1,11]		2942
Non fatal stroke	430 / 10269 (4,2%)	435 / 10267 (4,2%)	0,99	[0,87;1,13]		2942
Non fatal MI	464 / 10269 (4,5%)	467 / 10267 (4,5%)	0,99	[0,88;1,13]		2942
The primary endpoint (if exists) appears in blod characters
Reference(s) used for data extraction: 2942: MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial.Lancet 2002 Jul 6;360:23-33 0:

Endpoint	Events rate		Absolute risk reduction (ARR)
Absolute risk reduction (for a follow-up of jul 1994 - may 1997)
Endpoint	Studied treat.	Control treat.	Absolute risk reduction (ARR)
Coronary event	10,35%	10,20%	0,15%
stroke (fatal and non fatal)	4,98%	5,05%	-0,07%
Cardiovascular death	8,55%	8,18%	0,37%
cardiovascular events	22,46%	22,52%	-0,06%
All cause death	14,08%	13,53%	0,55%
Non fatal stroke	4,19%	4,24%	-0,05%
Non fatal MI	4,52%	4,55%	-0,03%

Meta-analysis of all similar trials:

TrialResults-center ID	TRC3698
Trials register #	NA